|Slideshows|January 3, 2019

Human Trafficking Training in Health Care

In the spirit of Human Trafficking Awareness Month, we hope this short quiz raises awareness when considering clinical vulnerability in victims.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe

Related Content

Intimate Partner Violence and Psychiatric Leadership: Clinical Perspectives

ByJames Rachal, MD

May 16th 2026

Anosognosia and the Criminalization of Schizophrenia: Implications for Clinical Practice

ByDavid Hager, MD, MS

May 11th 2026

The Psychiatrist’s Preview of Legal Cases Against Big AI

ByAllen Frances, MD,Joseph R. Simpson, MD, PhD,Joseph M. Pierre, MD

April 21st 2026

Hotel Homicide, Hotel Suicide, and "The White Lotus"

BySusan Hatters Friedman, MD, MSt, DFAPA,Samuel Rosenblatt, MD

March 24th 2026

Multilayered Trauma, One PTSD Diagnosis?

ByErica Browne,Catalina Belean, MD

March 9th 2026

Latest CME

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Video

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Video

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Patricia Junquera, MD; Maria Collado, MD; Erin C. Crown, MHSPAS, PA-C, Psych-CAQ

Video

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

Video

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Human Trafficking Training in Health Care

Related Content

Intimate Partner Violence and Psychiatric Leadership: Clinical Perspectives

Anosognosia and the Criminalization of Schizophrenia: Implications for Clinical Practice

The Psychiatrist’s Preview of Legal Cases Against Big AI

Hotel Homicide, Hotel Suicide, and "The White Lotus"

Multilayered Trauma, One PTSD Diagnosis?

Latest CME

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

Zuranolone in the Room: Closing the Gap in Postpartum Depression Care

The Psychiatric Impact of Cannabis Policy: More Than a Legal Framework

FDA Accepts NDA for AXS-12 for the Treatment of Cataplexy in Narcolepsy

Classic Drug, New Target: Lithium as Disease-Modifying in Alzheimer Dementia

Oral Cannabinoid From MediPharm Shows Significant Reduction in Agitation in Alzheimer Disease and Dementia